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Abstract
Objective—To study the prevalence of psychiatric comorbidity based on reference standard
diagnostic criteria in patients with human immunodeficiency virus (HIV). Psychiatric illness is
common in patients with HIV and has been associated with negative health behaviors and poorer
clinical outcomes. Among those persons with psychiatric illness, psychiatric comorbidity (multiple
simultaneous diagnoses) is associated with increased psychiatric severity and higher HIV risk
behaviors.
Methods—A total of 152 consecutively presenting HIV+ patients at an academic medical center
in the southeastern US completed a modified Structured Clinical Interview for DSM-IV (Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition) that assessed mood, anxiety, and substance
use disorders in the past year and past month.
Results—Fifty percent and 33% of patients had a past-year and past-month diagnosis, respectively.
The most common diagnoses were mood disorders (32% past year/21% past month) followed by
anxiety (21%/17%) and substance use disorders (22%/11%). Half of those with past-year disorders
and 40% of those with past-month disorders met the criteria for multiple diagnoses. Of those with a
mood disorder in the past month, 53% also had an anxiety or substance use disorder; of those with
an anxiety disorder, 62% also had a mood or substance use disorder; and of those with a substance
use disorder, 63% also had a mood or anxiety disorder. Psychiatric comorbidity was associated with
younger age, White non-Hispanic race/ethnicity, and greater HIV symptomatology.
Conclusions—Comorbidity of mood, anxiety, and substance use disorders was the exception
rather than the rule in this sample. Potential co-occurring disorders should be considered for HIV+
patients presenting with a psychiatric diagnosis.
Keywords
psychiatric comorbidity; prevalence; HIV; depression; anxiety; substance use
Address correspondence and reprint requests to Bradley N. Gaynes, Department of Psychiatry, CB# 7160, University of North Carolina
at Chapel Hill, Chapel Hill, NC 27599-7160. bradley_gaynes@med.unc.edu.
NIH Public Access
Author Manuscript
Psychosom Med. Author manuscript; available in PMC 2010 July 9.
Published in final edited form as:














Co-occurring mental illness has direct clinical relevance for patients infected with human
immunodeficiency virus (HIV). Mental illness worsens functional impairment and quality of
life (1) and is associated with a more rapid and harder-to-treat progression of HIV disease
(2–4). These worsened outcomes are believed to be related to both behavioral mechanisms
(noncompliance with HIV medications) (5) as well as direct biological measures (6,7). Given
this risk, many medical professionals have used the identification of a psychiatric illness
coexisting with HIV infection as a red flag to target for more aggressive and comprehensive
clinical management (8–10).
Co-occurring mental illness may play a key role in the southeastern US—the region with a
fast-rising HIV epidemic (11). In our earlier work in an infectious disease clinic setting with
a patient population reflective of the HIV+ population in the Southeast, we assessed a
consecutive sample of 152 patients with a reference standard psychiatric diagnostic interview
(12). We documented past-year prevalence for any substance use disorder and any mood/
anxiety disorder of 20% and 41%, respectively, consistent with prior reports on increased rates
of psychiatric morbidity in HIV+ populations (13,14). Each of these psychiatric disorders, on
their own, has been associated with decreased access to highly active antiretroviral therapy
(HAART) and poor antiretroviral adherence (15–17).
Yet, for many individuals with mental illness, having more than one psychiatric diagnosis
concurrently is common, and this psychiatric comorbidity is strongly related to greater
psychiatric severity (18) and higher rates of suicide attempts (19). Psychiatric comorbidity is
further linked to worse medical outcomes (20), likely in part through the mechanism of
nonadherence to medication treatment (21). Psychiatric comorbidity is particularly worrisome
for patients with HIV because of the influence of psychiatric illness on risk behaviors,
medication adherence, and clinical course and the fact that psychiatric comorbidity makes each
of the component psychiatric illnesses more difficult to treat. Psychiatric comorbidity in
patients with HIV can portend worse psychiatric and HIV outcomes as well as increased risk
behaviors for secondary transmission of HIV (22,23). Of particular concern for patients with
HIV is the association of unmanaged psychiatric illness with nonadherence to HAART (5) and
the subsequent development of antiretroviral-resistant HIV (24).
Despite this clinical relevance, we could find no reference standard-based report on the
prevalence of psychiatric comorbidity in the HIV+ population apart from one report restricted
to past-year psychiatric diagnoses in patients with HIV who received methadone treatment
(25). Accordingly, we report here on psychiatric comorbidity, both in the past month and the
past year, as established by reference standard Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition (DSM-IV) diagnoses, in a consecutive population of HIV+ patients




The study population comprised 152 HIV+ patients consecutively recruited at an infectious
disease clinic in an academic medical center in the southeastern US as part of a validation study
of a psychiatric screening instrument (12). All patients were considered eligible for recruitment
who kept a scheduled appointment between August 2003 and June 2004, were HIV+, either
were new or had not previously completed the screening instrument, were at least 18 years old,
were English-speaking, and were mentally competent to provide informed consent as assessed
by their medical provider. After complete description of the study to the subjects, written
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informed consent was obtained. All study procedures were approved by the Institutional
Review Board of the University of North Carolina at Chapel Hill.
Measures
Participants completed the Structured Clinical Interview for DSM-IV (DSM-IV (Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition) (SCID) (26) administered by a trained
psychiatry research interviewer with 5 years of experience in psychiatry research and 3 years
of experience in the administration of SCID. Patients completed the interview either in person
or by telephone. Previous research has indicated that the SCID, administered in person or by
telephone, has comparable test characteristics (27–30). The interviewer assigned final
diagnoses after the interview in consultation with a psychiatrist (B.N.G.). Diagnoses were
assigned as being present or absent within the past year and within the past month (current).
Only diagnoses included in the Substance Use, Mood, and Anxiety sections of the SCID were
considered because these disorders were targeted by the screening instrument as the focus of
the parent validation study and because they are the most prevalent psychiatric disorders among
patients with HIV. Both the interviewer and the psychiatrist were blinded to the results of the
previously administered screening instrument that was the focus of the validation study.
During the interview, participants also provided information on sociodemographic
characteristics and if they had experienced each of a list of HIV-related symptoms in the past
6 months: persistent headaches, fevers, oral pain, white patches in the mouth, rashes, nausea
or loss of appetite, eye trouble, sinus infection, numbness in the extremities, persistent cough,
diarrhea, weight loss, and (for women only) vaginal discharge. Trained chart abstractors
collected information on current CD4 counts and antiretroviral treatment status from
participants' medical records.
Analyses
We calculated past-year and past-month prevalence estimates for specific diagnoses and for
measures of comorbidity. We used logistic regression models to evaluate sociodemographic
and clinical characteristics as predictors of psychiatric morbidity and comorbidity. In modeling
continuous variables (age and CD4 count), we compared a restricted quadratic spline
specification with knots at the 10th, 50th, and 90th percentiles to a simple linear specification
in bivariate analyses, and retained the former only if indicated by a statistically significant
increase in the log likelihood (p < .05). We visually confirmed the appropriateness of the chosen
specification with locally weighted scatterplot smoothing (lowess) graphs. To limit the
influence of small numbers of observations at extreme values, we coded all values of CD4
>1000 (n = 5) to 1000. We assessed the global fit of each final model using Pearson and Hosmer-
Lemeshow goodness-of-fit statistics, and we examined residuals for observations that were
overly influential in the estimation of coefficients (31). We calculated the area under the




As described previously (12), 185 patients consented to participate, representing 82% of all
patients invited to participate and 65% of all eligible patients who kept appointments during
the recruitment period. Although there were no written records of reasons for nonparticipation,
the study staff reported that the most common reasons for nonparticipation were expressed
lack of interest in the study or anticipated difficulty in scheduling the follow-up interview.
Lack of available study personnel constituted the only reason eligible patients were not invited
to participate.
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SCIDs were successfully completed with 152 (82.2%) of the 185 participants. Of the 33
participants who did not complete the SCID, 28 were not successfully recontacted and 5 refused
to complete the SCID when recontacted, citing lack of either time or interest. The distribution
of age, race, sex, and health insurance status did not differ significantly between participants
who completed the SCID and those who were lost to follow-up. Twenty-one (13.8%) SCIDs
were conducted in person and 131 (86.2%) were conducted by phone. Those participants
interviewed in person and by phone were comparable on all background characteristics and
reported similar prevalence of mood and anxiety disorders, but a higher prevalence of substance
use disorders was reported among those interviewed in person (24% versus 8%, p = .03).
Results did not change appreciably when analyses were restricted to those interviewed by
phone or when the interview format was included as a covariate in multivariable models.
Sample Characteristics
Participants were primarily 30 to 50 years old (range = 20–65 years; mean ± standard deviation
= 40.5 ± 8.8 years) (data not shown). Approximately one third of the participants were female.
Approximately three quarters were African-American, with the remainder primarily
Caucasian. Thirty-six percent received public health insurance and 28% were uninsured.
Participants were similar to the clinic patient population in gender and insurance status but
were younger on average (mean age = 40.4 versus 42.5 years, p = .01) and more likely to be
African-American (72% versus 59%; p < .01).
Prevalence
Psychiatric disorders affected half of the participants in the past year and one third in the past
month (Table 1). Mood disorders were the most prevalent (32% in the past year, 21% in the
past month), followed by anxiety disorders (21% and 17%) and substance use disorders (22%
and 11%). Depression (major depressive disorder or depressive disorder not otherwise
specified) accounted for nearly all diagnoses of mood disorders. Posttraumatic stress disorder
was the most common anxiety disorder. Alcohol and crack/cocaine use accounted for nearly
all substance use disorders, as documented in other research on the HIV epidemic in the South.
Apart from panic disorder, most diagnoses of anxiety disorders in the past year were also
present in the past month, suggesting low incidence and relatively long duration. In contrast,
mood and substance use disorders tended to have higher prevalence in the past year than in the
past month, indicating either the resolution or remission of between 25% and 50% of cases
occurring in the preceding year.
Comorbidity
A substantial proportion of the participants with psychiatric illness had multiple diagnoses
(Table 2). Of the participants who in the past year had at least one diagnosis (cases), half had
two or more diagnoses. Forty percent of past-month cases had multiple diagnoses. When
attention was restricted to mood and anxiety disorders only, approximately 30% of cases in
the past year and the past month had multiple disorders.
Having a single mental health diagnosis was the exception (Figure 1). Of the 50 individuals
with at least one psychiatric diagnosis, 32 (64%) had a mood disorder, 26 (52%) had an anxiety
disorder, and 16 (32%) had a substance use disorder. Of the 32 participants with a mood
disorder, fewer than half (15/32 or 47%) had a mood disorder alone, with the remainder having
co-occurring anxiety and/or substance use disorders. Similarly, of the 26 participants with an
anxiety disorder, fewer than half (10/26 or 38%) had an anxiety disorder alone; of the 16
participants with a substance use disorder, fewer than half (6/16 or 38%) had a substance use
disorder alone. The comorbidity between mood and anxiety disorders was the most common.
Of those persons with an anxiety disorder, over half (14/26 or 54%) had a mood disorder
whereas of those with a mood disorder, nearly half (14/32 or 44%) had a coexisting anxiety
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disorder. About one third of those with comorbid anxiety and mood disorders also met the
criteria for a substance use disorder (5/14 or 36%).
Predictors of Psychiatric Morbidity and Comorbidity
In multivariable logistic regression models predicting current psychiatric morbidity and
comorbidity, greater age was predictive of lower prevalence of any psychiatric disorder, any
anxiety disorder, and ≥2 and ≥3 disorders (Table 3). Point estimates for the remaining two
outcomes (any mood disorder and any substance disorder) were in the same direction but not
statistically significant. Point estimates for associations of female gender with outcomes were
not statistically significant but the direction of all associations was consistent with expectations
(higher prevalence of mood and anxiety disorders; lower prevalence of substance use disorders;
and higher prevalence of comorbidity). White non-Hispanic race/ethnicity was predictive of
greater risk of mood, anxiety, and comorbid disorders, and point estimates for all other
outcomes were in the same direction.
Patients who received antiretroviral therapy were significantly less likely to have any
psychiatric disorder, any anxiety disorder, or any substance disorder, with point estimates for
other outcomes in the same direction. A greater number of reported HIV-related medical
symptoms was positively associated with five out of six outcomes, with the 6th point estimate
(any substance use disorder) in the same direction. The relationship between HIV
symptomatology and psychiatric morbidity did not change when HIV symptoms potentially
caused by mental illness (nausea/loss of appetite and weight loss) were excluded.
Health insurance status, educational attainment, and CD4 count were not significantly
associated with any outcome nor was the direction of point estimates consistent across
outcomes. The overall models demonstrated good predictive power as measured by the area
under the ROC curve, with all areas between 0.77 and 0.89. All models demonstrated
satisfactory goodness-of- fit.
Most independent variables showed similar associations with disorders in the past year (data
not shown), with the following exceptions: lack of private health insurance was predictive of
any psychiatric disorder, and college education was predictive of any anxiety disorder.
Discussion
For those HIV+ patients with a nonpsychotic mental health disorder, having a single mental
health diagnosis was the exception rather than the rule. Overall, half of the patients with a
reference standard diagnosis of a past-year mental health disorder and 40% of the patients with
a past-month diagnosis met the criteria for multiple diagnoses. More than half of the patients
with a past-month diagnosis of a mood disorder also had a co-occurring anxiety or substance
use disorder; more than half of the patients with an anxiety disorder diagnosis also had a co-
occurring mood or substance use disorder; and more than half of the patients with a substance
use disorder diagnosis also had a co-occurring mood or anxiety disorder.
The relationship between psychiatric comorbidity and medical illness in general is clinically
important because of the association with poorer medication compliance (21) and worse
outcomes for both the psychiatric illness (19) and the medical illness (32–34). In HIV+ patients,
in particular, the relationship between psychiatric comorbidity and clinical course is especially
important because of the potentially life-threatening risk of development of antiretroviral-
resistant HIV (24). As demonstrated by our results, the prevalence of comorbid psychiatric
illness in patients with HIV is substantial.
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The frequency of co-occurring psychiatric disorders in this sample has important implications
for medical professionals providing care for HIV+ patients. First, for any patient in whom a
single psychiatric disorder is identified, the possibility of additional co-occurring disorders
should be strongly considered. Second, comorbidity may affect the psychiatric treatment plan.
For example, a patient with major depression and a co-occurring anxiety disorder may require
a lower initial antidepressant dose (because of susceptibility to activation side effects) and, in
general, would require eventually a higher final antidepressant dose than a patient with major
depression alone (35,36). Similarly, substance abuse treatment programs may prove ineffective
for individuals with a co-occurring depressive disorder that is not identified and addressed
(37). Third, if a patient with an identified psychiatric disorder fails to respond to the current
psychiatric treatment plan, the clinician should consider a more thorough psychiatric diagnostic
evaluation to assess for additional co-occurring disorders. These conclusions are particularly
germane given the reported effectiveness of successful psychiatric treatment in improving HIV
medication adherence and clinical outcomes (9,38,39); such benefits may not be realized if the
treatment plan does not address co-occurring disorders.
Relative to the general population, this sample of HIV+ patients demonstrated a higher
prevalence of psychiatric illness overall but showed a similar pattern of comorbidity among
those with at least one diagnosis. The recently completed National Comorbidity Survey
Replication (NCS-R) estimated that 34% of the adult English-speaking US population met the
criteria for a DSM-IV disorder in the past 12 months compared with 49% in the present sample
(18). In both the NCS-R and the present sample, however, 50% of cases had a single disorder
and 50% had comorbid disorders.
The high prevalence of mood, anxiety, and substance use disorders observed in the present
study is consistent with previous reports of increased rates of psychiatric morbidity in HIV+
individuals. In a national sample of HIV+ individuals engaged in medical care, approximately
half reported significant current mental health symptoms, 13% reported symptoms of current
drug dependence, and 19% reported heavy drinking (13); approximately one in eight persons
were estimated to have mental health symptoms co-occurring with problematic alcohol or drug
use (40). US studies based on diagnostic criteria rather than screening instruments have
generally found major depressive disorder to be approximately twice as common in HIV+
individuals relative to comparable controls, with prevalence estimates ranging from 4% to 23%
(median 8%) (14). In the only identified study to report estimates of psychiatric comorbidity
based on diagnostic criteria in HIV+ individuals, Winiarski and colleagues reported that, of
139 HIV+ patients who received methadone treatment, 71% merited at least one additional
past-year psychiatric diagnosis besides opioid dependence, and the mean number of past-year
psychiatric diagnoses was 3 (range = 1–7) (25). Our finding that 63% (10/16) of patients with
a substance use disorder had at least one additional psychiatric diagnosis is consistent with the
Winiarski report. Of note, this prior study assessed past-year diagnoses that would be expected
to produce higher comorbidity estimates than past-month assessments. Further, the Winiarski
study included psychotic disorders and antisocial and borderline personality disorders. We
report here only on mood, anxiety, and substance use disorders; thus, our estimates of
psychiatric comorbidity are likely to be underestimates of the co-occurrence of all psychiatric
disorders.
In this sample, patients with a psychiatric illness were one fourth as likely to be on antiretroviral
therapy as patients with no psychiatric illness after controlling for key covariates, such as CD4
count and insurance status. This finding may reflect a tendency on the part of HIV providers
either not to initiate antiretroviral therapy in patients with a mental illness or to delay initiation
until depression and substance use issues—key barriers to medication adherence—are being
successfully addressed (16,17). Alternatively, patients with a psychiatric illness may be more
likely to discontinue antiretroviral therapy (41). White non-Hispanics were more likely than
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patients of other race/ethnicities to have mood, anxiety, and multiple psychiatric disorders; the
odds ratio for multiple disorders was strikingly large but also had a very wide confidence
interval, reflecting substantial instability around the point estimate due to a small number of
patients of other race/ethnicities with multiple disorders.
Although the present study only recruited patients from one infectious disease clinic, the
demographic and transmission characteristics of the clinic's patient population mirror the
epidemiologic dynamics of HIV/AIDS (acquired immunodeficiency syndrome) in the
southeastern US. Specifically, approximately two thirds of patients are African-American with
the remainder primarily White; two thirds are male; many come from poor and rural areas; and
heterosexual intercourse represents an increasingly important mode of transmission (42,43).
The clinic, located in a small urban area, does not serve a specialized (e.g., inner city or
primarily injection drug using) patient population but rather serves nearly all persons living
with HIV in the immediate vicinity and a large proportion of those within several hours' driving
distance. The consecutive sampling design used in the current study yielded a sample largely
reflective of the overall clinic population. Consecutive sampling, at the same time avoiding
biases inherent in convenience samples, tends to oversample patients with more frequent HIV
medical appointments. Patients with psychiatric comorbidity may require more frequent
appointments, but mental illness has also been cited as a barrier to accessing care (44); thus,
any resulting bias in our estimates of prevalence and comorbidity is uncertain in direction. The
present sample had a younger mean age and a higher proportion of African-American patients
compared with the clinic as a whole, possibly reflecting either more frequent appointments or
greater willingness to participate in these groups.
The South has received increasing attention in recent years as the US region with the fastest
growing HIV epidemic. Further, the transition of the HIV epidemic is most pronounced in the
South, as HIV increasingly affects women, minorities, the poor, and those from rural areas and
is transmitted via heterosexual intercourse (11,42,43,45). Although many explanations of the
epidemic's disproportionate impact on the South have been proposed, efforts to turn the tide
continue to face considerable challenges (11). Nationally, HIV prevention initiatives are
emphasizing secondary prevention (reducing transmission risk behaviors among HIV+
individuals) as a primary strategy in stemming the HIV epidemic (46). Secondary prevention
efforts may prove particularly challenging in the context of high prevalence of mental illness,
because psychiatric disorders and particularly psychiatric comorbidity predict higher and more
intractable risk behavior profiles in persons with HIV (23,47).
Although the SCID is a widely recognized and utilized reference standard instrument for the
reliable and valid assignment of DSM-based diagnoses, it is nevertheless likely subject to some
measurement error in assessing the unmeasurable latent construct of psychiatric illness. The
stringent and detailed criteria required for the assignment of a given diagnosis suggest that the
SCID may be relatively more specific than it is sensitive—that is, the SCID may be more likely
to miss a case than flag a false-positive. In such a situation, the reported estimates of prevalence
and comorbidity would be underestimates. Psychiatric measurement remains a considerable
challenge and the focus of extensive research. In the present study, all SCID interviews were
conducted by the same interviewer and all diagnoses were reviewed by the same psychiatrist
to ensure consistency.
A lower reported prevalence of substance use disorders was observed in those completing the
SCID by telephone compared with those interviewed in person. This difference could be due
to selection (i.e., substance users being more likely to desire an in-person interview) or
differential reporting (e.g., more underreporting of substance use by phone). Before the SCID,
all participants completed an initial in-person mental health and substance use screen as part
of the parent validation study. Those who ended up selecting an in-person format for the SCID
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were more likely to have screened positive for probable substance use on the in-person screen
than those who ended up electing to complete the SCID by telephone (62% versus 33%; p = .
01), whereas the two groups were equally likely to screen positive for probable mental illness
(71% versus 68%; p = .75). These results suggest that the difference in observed prevalence
of substance use disorders by the SCID interview format is more likely a function of selection
than differential reporting.
The findings presented in this study represent the first report of reference standard-based
psychiatric comorbidity estimates in a general HIV+ patient population. We find that
comorbidity of mood, anxiety, and substance use disorders is the exception rather than the rule,
suggesting that consideration of potential co-occurring disorders should be included in the
development of a treatment plan for an HIV+ patient presenting with a psychiatric diagnosis.
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Comorbidity of past-month mood, anxiety, and substance use disorders among 50 HIV+
patients with at least one disorder.
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TABLE 1
Prevalence of Past-Year and Past-Month Mood, Anxiety, and Substance Use Disorders and
Comorbidity, 152 HIV+ Patients
Disordera Past Year, n (%) Past Month, n (%)
Overall
 Any disorder 74 (50) 50 (33)
Mood disorders
 Any mood disorder 48 (32) 32 (21)
 Major depressive disorder 24 (16) 17 (11)
 Depressive disorder NOS 16 (11) 13 (9)
 Substance-induced mood disorder 4 (3) 1 (1)
 Other mood disorderb 5 (3) 1 (1)
Anxiety disorders
 Any anxiety disorder 32 (21) 26 (17)
 Posttraumatic stress disorder 10 (7) 9 (6)
 Panic disorder 8 (5) 4 (3)
 Anxiety disorder NOS 6 (4) 5 (3)
 Social phobia 4 (3) 4 (3)
 Specific phobia 5 (3) 5 (3)
 Obsessive-compulsive disorder 2 (1) 2 (1)
Substance use disorders
 Any substance use disorder 33 (22) 16 (11)
 Alcohol 17 (11) 12 (8)
 Crack/cocaine 21 (14) 7 (5)
 Cannabis 3 (2) 1 (1)
Comorbidity
 Any mood/anxiety disorder 62 (41) 44 (29)
 Both mood and anxiety disorders 18 (12) 14 (9)
 Substance use and mood/anxiety disorders 21 (14) 10 (7)
 ≥2 disorders 37 (24) 20 (13)
 ≥3 disorders 10 (7) 8 (5)
a
Diagnosed with the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition).
b
Dysthymia, bipolar I or II, adjustment disorder with depressed mood, bereavement, or mood disorder not otherwise specified.
HIV = human immunodeficiency virus; NOS = not otherwise specified.
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TABLE 2
Comorbidity of Past-Year Past-Month Mood, Anxiety, and Substance Use Disorders, 152
HIV+ Patients
Number of Disorders
Past Year (%) Past Month (%)
Respondentsa Casesb Respondentsa Casesb
Mood, anxiety, and substance use disorders
 0 51 – 67 –
 1 24 50 20 60
 2 18 37 8 24
 ≥3 7 14 5 16
Mood and anxiety disorders only
 0 59 – 71 –
 1 29 71 20 68
 2 9 23 7 25
 ≥3 3 6 2 7
a
Percent of all respondents (n = 152).
b
Percent of all respondents with at least one disorder (past year: n = 74; past month: n = 50).
HIV = human immunodeficiency virus.
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